Statins Show Modest Survival Benefit in Colorectal Cancer patients, suggests study

A new study published in the Journal of American Medical Association showed that commencing statin therapy showed a slight enhancement in survival rates for individuals undergoing treatment for colorectal cancer (CRC).

Observational research has indicated a potential increase in survival rates for individuals with CRC who begin taking statins after being diagnosed. However, these studies are susceptible to time-related biases and informative censoring. Hence, this study evaluated the link between starting statin therapy after treating CRC and the mortality rates specific to CRC and overall mortality, utilizing target trial emulation.

This nationwide cohort study utilized data from the Korean National Health Insurance Service claims spanning from January 1, 2005, to December 31, 2015. The study included adults who were newly diagnosed with CRC and had not been prescribed statins in the preceding 6 months. The starting point, referred to as time zero, was the date of the first CRC treatment. A clone-censor weight method, along with stabilized inverse probability of censoring weights, simulated the initiation of treatment within a grace period of 6 months.

The data underwent analysis at 3-month intervals over a 60-month follow-up period from August 22, 2023, to November 22, 2025. The main outcome measured was CRC-specific mortality, while the secondary outcome was all-cause mortality. Weighted pooled logistic regression was employed to calculate hazard ratios (HRs), 60-month marginal survival probabilities, and risk variations. Sensitivity analyses were conducted to address potential biases, such as immortal time bias and prevalent user bias. The same methodology was replicated in a cohort study involving individuals with ischemic heart disease as a positive control.

Out of 88,516 individuals, 2071 started taking statins while 86,445 did not. Beginning statin treatment was linked to a slightly reduced risk of dying specifically from colorectal cancer when compared to not starting statins. The overall mortality was also lower, but the difference was not statistically significant.

The absolute variances in colorectal cancer-specific and overall mortality after 60 months were minimal. Traditional assessments provided more favorable estimations. In a group used as a comparison with heart disease, starting statins was connected to decreased overall mortality but not specifically to cardiovascular disease-related deaths.

Overall, the perceived advantage in survival linked to starting statins after colorectal cancer therapy significantly decreased once factors like immortal time bias, prevalent user bias, and informative censoring were considered. These results underscore the importance of the research design in observational pharmacoepidemiology.

Reference:

Woo, H.-T., & Shin, A. (2026). Statin initiation and mortality after colorectal cancer treatment. JAMA Network Open, 9(9), e2633680. https://doi.org/10.1001/jamanetworkopen.2026.33680